May 24 (Reuters) – Biopharmaceutical company Theravance Inc
said it licensed its technology to manufacture
antibiotic Vibativ to specialty medicines maker Hospira Inc
.
The company would purchase from Hospira more than a majority
of its Vibativ 750 mg dosage form requirements during the
five-year agreement, Theravance said in a regulatory filing.
Vibativ is approved in Europe for the treatment of adults
with nosocomial pneumonia and for bacterial skin infections in
the United States and Canada.
Theravance said in January it was evaluating global
commercialization alternatives for Vibativ after partner
Astellas Pharma terminated the development and
marketing agreement for the antibiotic.
Shares of Theravance closed at $21.83 on Thursday on the
Nasdaq, while those of Hospira closed at $31.98 on the New York
Stock Exchange.
(Reporting by Balaji Sridharan in Bangalore; Editing by Sriraj
Kalluvila)
